Rovatirelin

DB15338InvestigationalSmall molecule

Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).

Mechanism: Pharmacologically active on Thyrotropin-releasing hormone receptor
Curator reviewed
Formula / weight: C₁₆H₂₂N₄O₄S · 366.44 g/mol (avg)
Code names: KPS-0373

Resolves to

Compound

UNII9DL0X410PYCAS204386-76-5

Structure

InChIKeyWTXWDXWZGJGIHV-URBCHYCLSA-NSMILESC[C@@H]1CCCN1C(=O)[C@H](CC1=CSC=N1)NC(=O)[C@H]1NC(=O)O[C@H]1C

Targets

P34981TRHR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Rovatirelin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account